{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Investigator safety reports are prepared for suspected unexpected serious adverse', 'reactions according to local regulatory requirements and GSK policy and are forwarded', 'to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE(s) or other', 'specific safety information (e.g., summary or listing of SAEs) from GSK will file it with', 'the IB and will notify the IRB/IEC, if appropriate according to local requirements.', '7.4.2.', 'Pregnancy', 'Details of all pregnancies in female subjects will be collected after the start of', 'Screening and until the follow-up contact.', 'If a pregnancy is reported then the investigator should inform GSK within 2', 'weeks of learning of the pregnancy and should follow the procedures outlined in', 'Appendix 7.', '7.4.3.', 'Medical Device Incidents (Including Malfunctions)', 'Procedures for documenting medical device incidents are provided in Appendix 6.', '7.4.4.', 'Electrocardiogram (ECG)', 'A Single 12-lead ECG will be obtained at Screening using an ECG machine provided by', 'the investigational site that automatically calculates the heart rate and measures PR, QRS,', 'QT, and QTc intervals.', 'The 12-lead ECG measurement and rhythm strip (10 seconds) will be obtained before', 'spirometry testing. ECG measurement should be obtained after subjects have rested for', 'approximately 5 minutes then the subjects should be placed in the supine position for the', 'ECG measurements. An ECG is only required at Screening Visit 1 for eligibility', 'assessment only.', 'The investigator, a designated sub-investigator, or other appropriately trained site', 'personnel will be responsible for performing and interpreting the 12-lead ECG at', 'Screening Visit 1. The investigator must provide his/her dated signature on the original', 'paper tracing, attesting to the authenticity of the ECG machine interpretation.', '7.5.', 'Genetics', 'Information regarding genetic research is included in Appendix 3', '8.', 'DATA MANAGEMENT', 'For this study subject data will be entered into GSK defined CRFs, transmitted', 'electronically to GSK or designee and combined with data provided from other', 'sources in a validated data system.', 'Management of clinical data will be performed in accordance with applicable', 'GSK standards and data cleaning procedures to ensure the integrity of the data,', 'e.g., removing errors and inconsistencies in the data.', '56']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Adverse events and concomitant medications terms will be coded using MedDRA', '(Medical Dictionary for Regulatory Activities) and an internal validated', 'medication dictionary, GSKDrug.', 'CRFs (including queries and audit trails) will be retained by GSK, and copies will', 'be sent to the investigator to maintain as the investigator copy. Subject initials', 'will not be collected or transmitted to GSK according to GSK policy.', '9.', 'STATISTICAL CONSIDERATIONS AND DATA', 'ANALYSES', '9.1.', 'Hypotheses', 'The primary purpose of this study is to demonstrate improvements in lung function for', 'subjects treated with UMEC/VI compared with UMEC for 24 weeks.', 'The primary endpoint is change from baseline in trough FEV1 at Week 24.', 'The null hypothesis is no difference between treatment groups (HO: T - S = 0), with', 'the alternative hypothesis that there is a difference between treatment groups (H1: T -', 'S # 0), where T is the mean change from baseline for UMEC/VI and S is the mean', 'change from baseline for UMEC.', '9.2.', 'Sample Size Considerations', 'The primary endpoint is change from baseline in trough FEV1 at Week 24. As an', 'important aim of the study is to compare UMEC/VI, UMEC and salmeterol with respect', 'to HRQoL the sample size has been calculated to provide sufficient power for the', 'comparison of the primary and secondary endpoint TDI, at Week 24.', 'The sample size calculations use a two-sided 5% significance level and an estimate of', 'between subject standard deviation for TDI of 2.94 units. The estimate of SD is based on', 'DB2113373 [Donohue, 2013], a study which consisted of treatment arms of UMEC/VI', '62.5/25, UMEC 62.5 VI (Vilanterol) 25mcg and placebo and is the value at Day 168 in a', 'subgroup of subjects who were ICS free at screening. Based on these data, 727 evaluable', 'subjects per treatment arm will be required to provide 90% power to detect a statistically', 'significant difference if the true difference is 0.5 units, 1/2 the MCID, between UMEC/VI', 'and UMEC. The smallest observed effect predicted to result in a statistically significant', 'difference between treatment groups is 0.31 units.', 'With this number of evaluable subjects per arm, the study will have >99% power', 'assuming a true treatment difference of 80mL between UMEC/VI and UMEC for trough', 'FEV1 at 24 weeks at the two-sided 5% significance level. This calculation uses a SD for', 'trough FEV1 of 240mL, based on prior results for trials comparing dual bronchodilators', 'versus single bronchodilators (Donohue, 2013; Bateman, 2013). The smallest observed', 'effect predicted to result in a statistically significant difference between treatment groups', 'is 25mL.', '57']\n\n###\n\n", "completion": "END"}